Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych VivasAddiction psychiatry — acute stimulant syndromes

Psych Vivas · Addiction psychiatry — acute stimulant syndromes

Stimulant intoxication and withdrawal — structured clinical viva

Fellowship viva on acute stimulant intoxication, MAP, medical toxicity, crash suicide risk, and absence of approved anti-craving standard with CM/psychosocial first-line framing.

clinical1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar on call. A 27-year-old woman smoked crystal methamphetamine for three days, presents with persecutory delusions and formication, BP 168/98, temperature 37.9°C, clear consciousness. ECG sinus tachycardia. She asks for 'something to stop the craving like methadone for heroin.' Partner wants her sectioned for schizophrenia forever. Discuss acute management, MAP versus primary psychosis, medical toxicity surveillance, withdrawal/crash risk, and the evidence position on anti-craving pharmacotherapy.

Interpretation

Reveal interpretationShowHide

This is an acute dual-diagnosis and toxicology viva, not a pure chronic addiction counselling station. Clear consciousness with persecutory delusions and formication after a multi-day ice binge favours MAP / substance-induced psychosis temporally linked to use, with dual formulation held open if symptoms persist after abstinence. Partner pressure for lifelong schizophrenia label is a classic trap — use timeline, collateral, and planned review rather than day-one diagnostic fatalism.[3]

Medical surveillance remains active even with T 37.9°C: serial vitals, ECG already done, watch for rising fever, chest pain, CK, agitation escalating to excited delirium-type risk. Behavioural ladder first; time-limited antipsychotic if psychosis is dangerous or impairing, with early review (NMA efficacy signals for MAP antipsychotics).[4]

Craving "like methadone" must be answered honestly: ASAM/AAAP — psychosocial first-line; no FDA-approved anti-craving/substitution standard analogous to OAT. You may mention selected trial signals (e.g. ADAPT-2 XR-naltrexone 380 mg IM every 3 weeks + bupropion XL 450 mg daily; mirtazapine 30 mg nocte in selected trials) as specialist discussions after acute stabilisation — not as ED methadone-equivalent starts.[1][5]

Crash plan: McGregor time course — early hypersomnia/fatigue, peak dysphoria ~day 2, improvement over 1–2 weeks — with explicit suicide monitoring and AOD follow-up. Name contingency management as the highest-yield psychosocial modality for ongoing stimulant use reduction.[2][6]

Legal status: assess risk and capacity; use jurisdiction-appropriate least-restrictive options if danger persists — do not invent section numbers for the wrong country. [1]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References6ShowHide
  1. [1]ASAM/AAAP Clinical Guideline Committee The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder J Addict Med, 2024.PMID 38669101
  2. [2]McGregor C, Srisurapanont M, Jittiwutikarn J, et al. The nature, time course and severity of methamphetamine withdrawal Addiction, 2005.PMID 16128721
  3. [3]McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study JAMA Psychiatry, 2013.PMID 23303471
  4. [4]Srisurapanont M, Likhitsathian S, Suttajit S, et al. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis Drug Alcohol Depend, 2021.PMID 33385693
  5. [5]Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder N Engl J Med, 2021.PMID 33497547
  6. [6]Pfund RA, Ginley MK, Boness CL, et al. Contingency Management for Drug Use Disorders: Meta-Analysis and Application of Tolin's Criteria Clin Psychol (New York), 2024.PMID 38863566
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousStimulant and methamphetamine use — structured clinical vivaAddiction psychiatry — stimulant and methamphetamine useNextStimulants and ADHD medications — cross-table vivaPsychopharmacology — stimulants and ADHD medications